KR102209475B1 - 우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도 - Google Patents

우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도 Download PDF

Info

Publication number
KR102209475B1
KR102209475B1 KR1020157020176A KR20157020176A KR102209475B1 KR 102209475 B1 KR102209475 B1 KR 102209475B1 KR 1020157020176 A KR1020157020176 A KR 1020157020176A KR 20157020176 A KR20157020176 A KR 20157020176A KR 102209475 B1 KR102209475 B1 KR 102209475B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
pregn
depressive disorder
composition according
nasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157020176A
Other languages
English (en)
Korean (ko)
Other versions
KR20150100884A (ko
Inventor
루이스 몬티
Original Assignee
페린 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 페린 파마슈티칼즈, 인코포레이티드 filed Critical 페린 파마슈티칼즈, 인코포레이티드
Publication of KR20150100884A publication Critical patent/KR20150100884A/ko
Application granted granted Critical
Publication of KR102209475B1 publication Critical patent/KR102209475B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157020176A 2012-12-28 2013-12-19 우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도 Active KR102209475B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261747167P 2012-12-28 2012-12-28
US61/747,167 2012-12-28
PCT/US2013/076497 WO2014105620A1 (en) 2012-12-28 2013-12-19 Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders

Publications (2)

Publication Number Publication Date
KR20150100884A KR20150100884A (ko) 2015-09-02
KR102209475B1 true KR102209475B1 (ko) 2021-01-28

Family

ID=49950051

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020176A Active KR102209475B1 (ko) 2012-12-28 2013-12-19 우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도

Country Status (11)

Country Link
US (1) US10322138B2 (https=)
EP (1) EP2938346B1 (https=)
JP (1) JP6283689B2 (https=)
KR (1) KR102209475B1 (https=)
CN (1) CN104936600B (https=)
AU (1) AU2013371025B2 (https=)
CA (1) CA2894686C (https=)
DK (1) DK2938346T3 (https=)
ES (1) ES2625778T3 (https=)
MX (1) MX369774B (https=)
WO (1) WO2014105620A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療
KR20260032486A (ko) 2023-06-04 2026-03-09 비스타젠 쎄라퓨틱스, 인크. 정신운동 또는 인지 수행의 개선에 사용하기 위한 1,3,5(10),16-에스트라테트라엔-3-일 아세테이트
US20250312356A1 (en) * 2024-04-08 2025-10-09 Vistagen Therapeutics, Inc. Treatment of dysmenorrhea

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6057439A (en) 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US20020123138A1 (en) 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5303703A (en) 1991-10-03 1994-04-19 Pherin Corporation Combined neuroepithelial sample delivery electrode device and methods of using same
US6331534B1 (en) 1994-08-04 2001-12-18 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate pain
US5563131A (en) * 1994-08-04 1996-10-08 Pherin Corporation Pregnane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6117860A (en) 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US6066627A (en) 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
US5994333A (en) 1994-08-04 1999-11-30 Pherin Corporation Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
PL331357A1 (en) * 1996-07-23 1999-07-05 Pherin Pharmaceuticals Steroids as neurochemical vno stimulators for soothing the symptoms of premenstrual tension and anxiety
US20030045514A1 (en) 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994028904A1 (en) 1993-06-15 1994-12-22 Pherin Corporation Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
US6057439A (en) 1994-08-04 2000-05-02 Pherin Corporation Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US20020123138A1 (en) 2000-11-30 2002-09-05 Jian Zhang Human VNO receptor (R1)

Also Published As

Publication number Publication date
ES2625778T3 (es) 2017-07-20
US20140187524A1 (en) 2014-07-03
EP2938346B1 (en) 2017-04-05
DK2938346T3 (en) 2017-06-12
CA2894686A1 (en) 2014-07-03
HK1210421A1 (en) 2016-04-22
WO2014105620A1 (en) 2014-07-03
KR20150100884A (ko) 2015-09-02
CN104936600B (zh) 2018-08-03
AU2013371025B2 (en) 2018-01-18
CA2894686C (en) 2021-05-04
JP6283689B2 (ja) 2018-02-21
MX369774B (es) 2019-11-21
AU2013371025A1 (en) 2015-07-09
EP2938346A1 (en) 2015-11-04
CN104936600A (zh) 2015-09-23
MX2015008454A (es) 2016-05-16
US10322138B2 (en) 2019-06-18
JP2016504361A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
KR102209475B1 (ko) 우울 장애를 치료하기 위한 프레그느-4-엔-20-인-3-온의 용도
AU2020259269B2 (en) Treatment of migraine
US8722652B2 (en) Acute treatment of social phobia
HK1210421B (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders
US20250312356A1 (en) Treatment of dysmenorrhea
HK40068177A (en) Treatment of migraine
HK40068177B (en) Treatment of migraine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6